Operative morbidity of living liver donors in Japan

Umeshita, Koji; Fujiwara, Kenji; Kiyosawa, Kendo; Makuuchi, Masatoshi; Satoh, Susumu; Sugimachi, Keizō; Tanaka, Kōichi; Monden, Morito

doi:10.1016/s0140-6736(03)14230-4

Cited by 251 publications

(203 citation statements)

References 13 publications

Supporting

Mentioning

189

Contrasting

Unclassified

Order By: Relevance

“…Potentially, our findings provide new insights into liver regeneration incidentally induced by various stresses, such as microbes, drugs, trauma, or surgical maneuvers. [38][39][40] Intestine-derived lipopolysaccharide (LPS) has been considered to be an initiator of the liver regeneration, 41 but our current findings clearly show that LPS is not essential for induction of liver regeneration (Fig. 5).…”

Section: Discussionmentioning

confidence: 57%

Contribution of Toll-like receptor/myeloid differentiation factor 88 signaling to murine liver regeneration

et al. 2005

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 57%

Contribution of Toll-like receptor/myeloid differentiation factor 88 signaling to murine liver regeneration

et al. 2005

View full text Add to dashboard Cite

“…12 Devastating complications of donors themselves undergoing salvage liver transplantation have also been reported. 13 Apart from these incidences, about 20% 14 and up to 67% of donors in one series 15 developed complications. It is undeniable that temporary morbidity affects all donors both physically and psychologically.…”

mentioning

confidence: 98%

Donor quality of life before and after adult-to-adult right liver live donor liver transplantation

Chan

Liu

et al. 2006

Liver Transpl

View full text Add to dashboard Cite

Donor right hepatectomy for adult-to-adult live donor liver transplantation (ALDLT) is a major surgical operation for the benefit of the recipient. Justification of procedure mandates knowledge of the possible physical and psychological negative effects on the donor. We prospectively and longitudinally quantified donor quality of life using generic and condition-specific questionnaires up to 1 year. The generic questionnaires were the Karnofsky Performance Status scale and the Chinese (Hong Kong) version of the Medical Outcomes Study 36-Item Short-Form Survey, which measures 8 health concepts: 4 physical components and 4 mental components. Within 1 year, 30 consecutive donors were included. These 11 male and 19 female donors (36.7% and 63.3%, respectively) had a median age of 35 years (range, 21-56 years). There was no donor mortality or major complications. Donor quality-of-life worsening was most significant in the first 3 postoperative months, particularly among the physical components. The physical and mental components returned to the previous levels in 6 to 12 months' time, though the Karnofsky performance scores were slightly lower at 1 year (P ϭ 0.011). Twenty-six (86.7%) donors declared that they would donate again if there were such a need and it were technically possible. It was noticed that older donors were more likely to express unwillingness to donate again. In conclusion, the temporary worsening of donor quality of life substantiates ALDLT as an acceptable treatment modality. Liver Transpl 12: 1529-1536, 2006.

show abstract

“…The complication rate for LT in North America and Europe ranges between 9.2% and 40% for the donor, and the mortality risk in donors is still 0.3% to 0.61% [64,65] . In contrast, data in Japan showed a complication rate of 12% with no perioperative deaths in living liver donors [66] . Meticulous surgical techniques and perioperative management, lean body mass in individual Japanese donors, and genetic factors were given as possible explanations for the zero transplant-related mortality rate in Japan.…”

Section: Liver Resectionmentioning

confidence: 87%

Current management strategy of hepatocellular carcinoma

Rampone¹,

Schiavone²,

Martino³

et al. 2009

WJG

121

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) still remains a considerable challenge for surgeons. Surgery, including liver transplantation, is the most important therapeutic approach for patients with this disease. HCC is frequently diagnosed at advanced stages and has a poor prognosis with a high mortality rate even when surgical resection has been considered potentially curative. This brief report summarizes the current status of the management of this malignancy and includes a short description of new pharmacological approaches in HCC treatment.

show abstract

Operative morbidity of living liver donors in Japan

Cited by 251 publications

References 13 publications

Contribution of Toll-like receptor/myeloid differentiation factor 88 signaling to murine liver regeneration

Contribution of Toll-like receptor/myeloid differentiation factor 88 signaling to murine liver regeneration

Donor quality of life before and after adult-to-adult right liver live donor liver transplantation

Current management strategy of hepatocellular carcinoma

Contact Info

Product

Resources

About